Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB reports ‘intense growth’ in 2010

UCB reports ‘intense growth’ in 2010

27th October 2010

UCB has noted the "intense" level of growth it has seen in its core business areas during the first nine months of 2010.

The pharmaceutical company has published its interim fiscal report for the year to date, revealing a revenue figure of 2.4 billion euros (2.1 billion pounds), up by nine percent year-on-year.

This was attributed primarily to the strong performance of its key new products Cimzia, Vimpat and Neupro, which are now being used by more than 170,000 patients worldwide.

In addition, the company saw improved sales for mature offerings such as Keppra, as well as making progress with the development of pipeline products including epratuzumab and Vimpat.

Roch Doliveux, chief executive officer of UCB, said: "Through these core products and progress in our pipeline, UCB is building a strong foundation for sustainable future company growth."

Earlier this month, UCB agreed a deal with Synosia Therapeutics which will see the two firms ally on the development of new neurology treatments.ADNFCR-8000103-ID-800160042-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.